2025-10-05 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the information you provided.

## TransMedics Group Inc. (TMDX) Analysis

**TransMedics Group Inc. is a medical technology company revolutionizing organ transplant therapy, focusing on preserving and assessing organs for transplantation.**

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 189.80%
*   **VOO Cumulative Return:** 73.75%
*   **Absolute Spread:** 117.0
*   **Relative Spread:** 59.5

**Analysis:** TMDX has significantly outperformed the S&P 500. The current spread of 117.0 places it in the 59.5th percentile of its historical spread range, indicating strong relative performance, but not at its absolute peak relative to VOO in the past.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2019-2021  | -18.0% | 83.5% | -61.0% | -0.0  | 0.7    |
| 2020-2022  | 94.0%  | 83.5% | 95.0%  | 0.0   | 2.1    |
| 2021-2023  | 65.0%  | 80.5% | 64.0%  | 0.1   | 2.7    |
| 2022-2024  | 130.0% | 85.5% | 109.0% | 0.1   | 2.1    |
| 2023-2025  | 111.0% | 85.5% | 48.0%  | 0.3   | 3.9    |

**Analysis:**

*   **CAGR:** TMDX shows impressive compounded annual growth rates in recent periods (2020-2025), but shows historical risks in the 2019-2021 period.
*   **MDD:** High Maximum Drawdown figures indicate substantial volatility.
*   **Alpha:** Consistently high positive Alpha values suggest TMDX's returns are largely independent of market movements, driven by company-specific factors.
*   **Beta:** Low Beta values indicate TMDX has exhibited low correlation to the S&P 500. However, Beta has slightly increased to 0.3 recently, suggesting some increased market sensitivity.
*   **Cap:** Market capitalization has increased in recent years.

### 2. Recent Stock Price Movement

*   **Current Price:** 115.69
*   **Last Market Data:** Price: 115.69, Previous Close: 116.07, Change: -0.33
*   **5-day Moving Average:** 114.31
*   **20-day Moving Average:** 115.43
*   **60-day Moving Average:** 115.73

**Analysis:**  The current price is slightly below the 20-day and 60-day moving averages, but above the 5-day moving average, suggesting a possible short-term upward trend after a period of consolidation. The slight decrease from the previous close (-0.33) is minor and doesn't necessarily indicate a strong negative trend on its own.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 52.40 (Neutral)
*   **PPO:** -0.06 (Neutral)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash
*   **Recent Relative Spread Change (20-day):** +0.1 (Short-term increase)
*   **Expected Return:** 50.7% (vs. S&P 500, long-term)

**Analysis:**

*   The MRI of 0.9 indicates the stock is considered a relatively safe investment.
*   An RSI of 52.4 is neutral, suggesting neither overbought nor oversold conditions.
*   A slightly negative PPO (-0.06) implies that the short-term moving average is slightly below the long-term moving average, but the difference is very minor.
*   The Hybrid Signal is a strong buy signal based on the indicators.
*   The positive change in relative spread over the last 20 days suggests short-term outperformance compared to the S&P 500.
*   The expected return of 50.7% over the long term is quite high, indicating significant potential upside.
*   The price change from the last market is slightly down.

### 4. Recent News & Significant Events

*   **Positive Coverage:** Several articles highlight TransMedics as a strong growth stock and potentially undervalued.
*   **Strategic Partnerships:** The partnership with Mercedes-Benz to launch an organ transport fleet in Italy is a significant positive development.  This suggests innovation and expansion.

**Analysis:**  Recent news is overwhelmingly positive, focusing on growth potential, undervaluation, and strategic collaborations. The Mercedes-Benz partnership is particularly noteworthy, indicating a commitment to innovation and market expansion.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.82)
*   **Target Price:** Average: $140.67, High: $170.00, Low: $114.00

**Analysis:** Analyst sentiment is generally positive with a "Buy" consensus. The average target price of $140.67 suggests a potential upside from the current price of $115.69. The range of target prices indicates some uncertainty among analysts, but the overall outlook is favorable.

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:** TransMedics has consistently beaten EPS estimates in recent quarters (particularly the last two), indicating strong financial performance and positive earnings surprises.  The 2024-10-28 was below the expected number

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | \$0.16B   | 61.38%        |
| 2025-03-31 | \$0.14B   | 61.47%        |
| 2024-12-31 | \$0.12B   | 59.21%        |
| 2024-09-30 | \$0.11B   | 55.94%        |
| 2024-06-30 | \$0.11B   | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-06-30 | \$0.32B   | 10.97%   |
| 2025-03-31 | \$0.27B   | 9.64%    |
| 2024-12-31 | \$0.23B   | 3.00%    |
| 2024-09-30 | \$0.21B   | 2.01%    |
| 2024-06-30 | \$0.19B   | 6.42%    |

**Analysis:**

*   **Revenue:** Revenue is steadily increasing.
*   **Profit Margin:** Profit margins are consistently high, indicating efficient operations.
*   **Equity:** Equity is growing, suggesting a strengthening financial position.
*   **ROE:** Return on Equity (ROE) is generally increasing, reflecting improved profitability relative to shareholder equity.

### 7. Overall Assessment

Based on the provided data, TransMedics Group Inc. (TMDX) appears to be a compelling investment opportunity. Key positives include:

*   **Strong Outperformance:** Significantly outperforms the S&P 500 with a high Alpha.
*   **Positive Momentum:** Recent price movement suggests a possible short-term upward trend.
*   **Favorable Indicators:** MRI indicates low risk, and hybrid signals suggest a buy.
*   **Positive News:** Recent news highlights growth potential and strategic partnerships.
*   **Analyst Support:** Analysts have a "Buy" consensus and a target price suggesting upside potential.
*   **Earnings Beat:** Consistently exceeding earnings estimates.
*   **Strong Financials:** Increasing revenue, high profit margins, and growing equity.

**However, also consider:**

*   **High Volatility:** Indicated by high MDD.
*   **Beta:** Beta has slightly increased to 0.3 recently, suggesting some increased market sensitivity.
*   **Not at its absolute peak relative to VOO:** The current spread of 117.0 places it in the 59.5th percentile of its historical spread range,
    indicating strong relative performance, but not at its absolute peak relative to VOO in the past.

**In conclusion, TMDX presents a growth opportunity with some associated risk due to its volatility. The positive momentum, strong financials, and analyst support suggest that it could be a worthwhile investment, especially for investors with a long-term perspective.**
